Brief: Contineum Therapeutics Expands Clinical Development Of PIPE-791

Contineum Therapeutics

18/11/2024 13:20

Nov 18 (Reuters) - Contineum Therapeutics Inc  CTNM.O :
    * CONTINEUM THERAPEUTICS EXPANDS CLINICAL DEVELOPMENT OF
PIPE-791
WITH FDA AUTHORIZATION OF ITS INVESTIGATIONAL NEW DRUG (IND)
APPLICATION FOR CHRONIC PAIN
    * CONTINEUM THERAPEUTICS INC: PHASE 1B STUDY FOR POTENTIAL
TREATMENT OF OSTEOARTHRITIS AND LOW BACK PAIN EXPECTED TO
COMMENCE IN Q1 OF 2025
    * CONTINEUM THERAPEUTICS INC - PHASE 1B STUDY FOR PIPE-791
TO
BEGIN IN Q1 2025
    * CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791
STUDY
EXPECTED IN EARLY 2026
    * CONTINEUM THERAPEUTICS INC - EXPECTS $213.9 MILLION CASH
TO FUND
OPERATIONS THROUGH 2027

Source text:  ID:nBw6NnGNca 
Further company coverage:  CTNM.O 

 ((Reuters.Briefs@thomsonreuters.com;))